These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19598262)

  • 41. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.
    Miyamoto M; Takano M; Iwaya K; Shinomiya N; Kato M; Aoyama T; Sasaki N; Goto T; Suzuki A; Hitrata J; Furuya K
    Br J Cancer; 2014 Jun; 110(12):2881-6. PubMed ID: 24853184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome.
    Zimmermann U; Woenckhaus C; Teller S; Venz S; Langheinrich M; Protzel C; Maile S; Junker H; Giebel J
    Histol Histopathol; 2007 May; 22(5):527-34. PubMed ID: 17330807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
    Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
    Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
    Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
    Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.
    Wang-Johanning F; Liu J; Rycaj K; Huang M; Tsai K; Rosen DG; Chen DT; Lu DW; Barnhart KF; Johanning GL
    Int J Cancer; 2007 Jan; 120(1):81-90. PubMed ID: 17013901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
    Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
    Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
    J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma.
    Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
    Anticancer Res; 2014 Apr; 34(4):2007-14. PubMed ID: 24692739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
    Itamochi H; Yoshida T; Walker CL; Bartholomeusz C; Aoki D; Ishihara H; Suzuki N; Kigawa J; Terakawa N; Ueno NT
    Gynecol Oncol; 2011 Sep; 122(3):641-7. PubMed ID: 21652059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
    Mabuchi S; Sugiyama T; Kimura T
    J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Takano M; Tsuda H; Sugiyama T
    J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 protein aggregation promotes platinum resistance in ovarian cancer.
    Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
    Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer.
    Liu J; Zheng M; Qi Y; Wang H; Liu M; Liu Q; Lin B
    Int J Oncol; 2018 Oct; 53(4):1774-1786. PubMed ID: 30066907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
    Park JT; Chen X; Tropè CG; Davidson B; Shih IeM; Wang TL
    Am J Pathol; 2010 Sep; 177(3):1087-94. PubMed ID: 20671266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
    Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
    Jinawath N; Vasoontara C; Jinawath A; Fang X; Zhao K; Yap KL; Guo T; Lee CS; Wang W; Balgley BM; Davidson B; Wang TL; Shih IeM
    PLoS One; 2010 Jun; 5(6):e11198. PubMed ID: 20585448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC).
    Lopes-Coelho F; Gouveia-Fernandes S; Gonçalves LG; Nunes C; Faustino I; Silva F; Félix A; Pereira SA; Serpa J
    Tumour Biol; 2016 Apr; 37(4):4813-29. PubMed ID: 26520442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.